Long-Awaited Torcetrapib Will Not Be Released, Too Risky

Elliott, William T.
May 2007
Travel Medicine Advisor;May2007, Vol. 17 Issue 5, p1
The article reveals that Pfizer Inc. will not release torcetrapib, a cholesteryl ester transfer protein inhibitor. The Investigator of Lipid Level Management to Understand Its Impact in Atherosclerotic Events trial showed an increase in death from all causes associated with the drug. It indicates that torcetrapib elevate high density lipoprotein levels while reducing low density lipoprotein levels.


Related Articles

  • Long-Awaited Torcetrapib Will Not Be Released, Too Risky.  // Primary Care Reports;May2007, Vol. 13 Issue 5, p1 

    The article discusses a study which found a possible mechanism for the lack of cardiovascular benefit in torcetrapib drug being developed by Pfizer Inc. According to the authors, torcetrapib, a cholesteryl ester transfer protein inhibitor, elevate high density lipoproteins while reducing low...

  • Cholesteryl ester transfer protein and its inhibition. Weber, Olaf; Bischoff, Hilmar; Schmeck, Carsten; Böttcher, Michael-Friedrich // Cellular & Molecular Life Sciences;Sep2010, Vol. 67 Issue 18, p3139 

    Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL)...

  • Torcetrapib associated with high mortality rates despite raising HDL. Raible, Eric // Cardiology Today;Jan2008, Vol. 11 Issue 1, p10 

    The article discusses research being done on the link between torcetrapib administration and mortality and morbidity. It references a study by Philip J. Barter and colleagues, published in "The New England Journal of Medicine." Study researchers found that torcetrapib plus atorvastatin increase...

  • Torcetrapib with Lipitor [atorvastatin].  // Pharmaceutical Executive;Dec2005, Vol. 25 Issue 12, p68 

    The article presents information about the drug Torcetrapib from Pfizer Inc. It is an ester transfer protein antagonist which raises the levels of high density lipoprotein. Pfizer is planning to market the drug as a fixed-combination cholesterol therapy with Lipitor, the top-selling drug in the...

  • Torcetrapib associated with high mortality rates despite raising HDL. Raible, Eric // Endocrine Today;1/10/2008, Vol. 6 Issue 1, p21 

    The article discusses a research on the effects of torcetrapib in patients at high risk for coronary events. It references a study by J. Barter et al, published in a 2007 issue of the "New England Journal of Medicine." Patients at high risk for major cardiovascular (CVD) events were randomly...

  • Aerobic Exercise, Lipoproteins, and Cardiovascular Disease: Benefits and Possible Risks. Herzberg, Gene R. // Canadian Journal of Applied Physiology;Dec2004, Vol. 29 Issue 6, p800 

    Aerobic exercise has been shown to reduce the risk of cardiovascular disease (CVD). This reduction is proportional to the intensity of the exercise. The reduction in CVD risk is at least partially mediated by changes in circulating lipoproteins resulting from adaptive changes in enzymes involved...

  • Apolipoprotein A-I Mimetic Peptides for the Treatment of Coronary Artery Disease. Yamada, Nicole K. // Current Cardiology Reviews;2005, Vol. 1 Issue 1, p81 

    High density lipoprotein (HDL) plays a critical physiological role in protecting the body against atherosclerosis by facilitating reverse cholesterol transport and the removal of oxidized phosphoplipids from artery walls. Apolipoprotein A-I (apoA-I) is the principal protein component of HDL that...

  • Quantification of Low-Density and High-Density Lipoproteins in Human Serum by Material Enhanced Infrared Spectroscopy (MEIRS). Petter, C. H.; Heigl, N.; Bakry, R.; Bonn, G. K.; Ritsch, A.; Huck, C. W. // Current Medicinal Chemistry;Dec2009, Vol. 16 Issue 34, p4601 

    A key risk factor in the development of atherosclerosis is a high concentration of serum low density lipoprotein (LDL)-cholesterol. The main purpose of this study was to assess the LDL and high density lipoprotein (HDL) content in human serum by employing near-infrared (NIR) spectroscopy and...

  • Morphological Changes of Aorta and Total Cholesterol, High Density Lipoprotein, Oxidized Low Density Lipoprotein, Nitric Monoxide and Lipide Peroxidation in Serum after Arcuate Nucleus Lesioned. Jin Xiao-Hong; Xu- Yi-Rong; Liu Bing; Yang Ya-an; Wang Min-Cheng; Wu Kai-Yun // Journal of US-China Medical Science;May2007, Vol. 4 Issue 5, p22 

    After arcuate nucleus of hypothalamus lesioned with monosodium glutamate and cutting infundibulum, morphological changes of aorta and total cholesterol, high density lipoprotein, oxidized low density lipoprotein, nitric monoxide and lipid peroxidation in serum were investigated to explore the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics